Patient characteristics
| . | No. or median (% or range) . | |
|---|---|---|
| . | BTKi-naïve (n = 32) . | On BTKi (n = 45) . |
| Age | 65 (48-76) | 67 (39-81) |
| Sex | ||
| Female | 16 (50%) | 19 (42%) |
| Male | 16 (50%) | 26 (58%) |
| Prior therapy | ||
| No | 24 (75%) | 25 (56%) |
| Yes, relapsed | 8 (25%) | 20 (44%) |
| IGHV | ||
| Mutated | 15 (47%) | 15 (33%) |
| Unmutated | 13 (41%) | 29 (65%) |
| Missing | 4 (12%) | 1 (2%) |
| FISH | ||
| del 17p | 4 (12%) | 14 (31%) |
| ALC | 69.7 (4.4-262.4) | 11.7 (1.0-106.3) |
| T cell: CLL cell | 0.04 (0.01-1.92) | 0.15 (0.02-7.11) |
| . | No. or median (% or range) . | |
|---|---|---|
| . | BTKi-naïve (n = 32) . | On BTKi (n = 45) . |
| Age | 65 (48-76) | 67 (39-81) |
| Sex | ||
| Female | 16 (50%) | 19 (42%) |
| Male | 16 (50%) | 26 (58%) |
| Prior therapy | ||
| No | 24 (75%) | 25 (56%) |
| Yes, relapsed | 8 (25%) | 20 (44%) |
| IGHV | ||
| Mutated | 15 (47%) | 15 (33%) |
| Unmutated | 13 (41%) | 29 (65%) |
| Missing | 4 (12%) | 1 (2%) |
| FISH | ||
| del 17p | 4 (12%) | 14 (31%) |
| ALC | 69.7 (4.4-262.4) | 11.7 (1.0-106.3) |
| T cell: CLL cell | 0.04 (0.01-1.92) | 0.15 (0.02-7.11) |
All characteristics given apply to the time of sample collection for the study. Patients on a BTKi had been treated for at least 5 months, 28 (62%) were on ibrutinib and 17 (38%) on acalabrutinib. Patients (n = 19) who contributed samples at baseline and again while on the BTKi are included in both groups. FISH, fluorescent in situ hybridization; IGHV, immunoglobulin heavy chain.